Lymphoma

Are there any new developments in Hodgkin lymphoma research that patients should know about? At the 2016 American Society of Hematology (ASH)... Learn More

Is there hope for people with Hodgkin Lymphoma? Dr. John Sweetenham, Executive Medical Director of the Huntsman Cancer Institute, says, “Yes!” On... Learn More

At the 2015 American Society of Hematology (ASH) conference, patient advocate Carol Preston and Dr. Christopher Yasenchak, from US Oncology Research, discuss... Learn More

At the 2014 American Society of Hematology (ASH) meeting, leading researcher Dr. John Sweetenham joined Patient Power to discuss developing research in... Learn More

As part of our coverage of the 2014 American Society of Hematology (ASH) annual meeting, Dr. Stephen Ansell from the Mayo Clinic... Learn More

During the 2014 American Society of Hematology (ASH) annual meeting, Dr. Ajay Gopal from Seattle Cancer Care Alliance joined Patient Power to... Learn More

During the 2014 American Society of Hematology (ASH) annual meeting, Dr. Catherine Bollard from Children’s National Health System joined Patient Power to... Learn More

During the 2014 American Society of Hematology (ASH) annual meeting, Dr. Philippe Armand from Dana-Farber Cancer Institute joined Patient Power to share... Learn More

Dr. Jeffrey Matous, medical director of the Colorado Blood Cancer Institute, explores treatment options for people who have experienced a Hodgkin lymphoma... Learn More

Dr. Stephen Ansell, an expert from the Mayo Clinic , shares why he feels it is an “optimistic time” for Hodgkin lymphoma... Learn More

Patient advocate George Florentine and Dr. Jeff Matous discuss important steps in preparing to take on relapsed/refractory Hodgkin lymphoma. The panel encourages... Learn More

Coping with a recurrence of cancer can lead to stress in many areas of a patient’s life. While some cancer patients may... Learn More

While Hodgkin lymphoma is more prevalent in a younger population, people over 40 years of age can still be affected. Patient Advocate... Learn More

Patient Advocate George Florentine discusses how he went from feeling great after successful first-line treatment to being thrown back into the ring... Learn More

A panel of Hodgkin lymphoma experts shares their words of advice to others, including the importance of finding an expert in this... Learn More

Hodgkin lymphoma patient advocates Meredith Wooten and Suzanne Hyte discuss the importance of trusting and working with your medical team to find... Learn More

Hodgkin lymphoma patient advocate Suzanne Hyte openly shares her uncertainty about her fertility following treatment and why she made the decision not... Learn More

Hodgkin lymphoma patient advocates Meredith Wooten and Suzanne Hyte share how they coped with additional treatments and side effects after relapsing. From... Learn More

Researchers are hoping that an improved understanding of Hodgkin Lymphoma at the biological level will translate to new, more effective treatment options.... Learn More

Dr. John Sweetenham, executive medical director at the Huntsman Cancer Institute, discusses the importance of clinic follow-up, regular surveillance and relatively frequent... Learn More

Cancer treatments not only take an emotional and physical toll, but also financial. Especially when it comes back. Hodgkin patient advocates Meredith... Learn More

Receiving the news that the Hodgkin Lymphoma relapsed can be devastating and cause a feeling of uncertainty especially with more aggressive treatments... Learn More

Being diagnosed with any kind of cancer takes an emotional toll. While Hodgkin’s lymphoma is often seen as a “good” kind of... Learn More

When your cancer comes back, how do you begin to tell others about it? Some people use social media, others make phone... Learn More

After enduring difficult initial treatments, patient advocates Meredith Wooten and Suzanne Hyte found small lumps on their collar bones. Tests confirmed the... Learn More

Dr. Anas Younes, a Hodgkin lymphoma expert at MD Anderson Cancer Center, is excited about the approval of brentuximab vedotin, the first... Learn More

Dr. Steven Park from the UNC Lineberger Comprehensive Cancer Center, explains trials for the use of brentuximab vedotin (Adcetris) in the frontline... Learn More

Dr. Stephen Ansell, a hodgkin lymphoma expert, explains exciting new treatment options for relapse refractory Hodgkin lymphoma with advancements of agents such... Learn More

Dr. Ajay Gopal, Director of Hematologic Malignancies at the Seattle Cancer Care Alliance, explains the results from a recent, large study using... Learn More

There continues to be excitement among Hodgkin lymphoma specialists about the use of a new drug, Brentuximab Vedotin, with new early data... Learn More

Can a new antibody drug conjugate, ADCETRIS (brentuximab vedotin), be the foundation of new combination therapies for patients with relapsed or refractory... Learn More

Dr. Ajay Gopal discusses his optimism at the state of the treatment for Hodgkin Lymphoma, a disease that primarily affects young adults.... Learn More